Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, coordinated team education, patient engagement, and workflow adjustments ...

Switching from IV to subcutaneous injection eases hard vein access, cuts clinic time, and boosts comfort with faster ...

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

This segment highlights the role of clinical guidelines in shaping treatment decisions in advanced melanoma, particularly ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World ...